| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Ron Hunt
|
Business associate |
5
|
1 | |
|
person
Vijay Lathi
|
Business associate |
5
|
1 | |
|
person
Philippe Chambon
|
Business associate |
1
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| 2005-01-01 | N/A | Founding of New Leaf | New Leaf | View |
| 2000-01-01 | N/A | Jeani Delagardelle joined Sprout | Sprout | View |
This document is a page from a confidential offering memorandum for 'New Leaf Ventures III, L.P.', a healthcare and life sciences investment fund targeting $375 million in capital. It outlines the partnership structure, appointing New Leaf Venture Associates III, L.P. as the General Partner and listing five managing principals (Chambon, Delagardelle, Hunt, Lathi, and Ratcliffe). The document bears a House Oversight Committee stamp, indicating it was part of a congressional investigation document production.
This document is a page from a corporate prospectus or due diligence report (marked Confidential, House Oversight) detailing the professional biographies of three Managing Directors at New Leaf (presumably New Leaf Venture Partners): Jeani Delagardelle, Ron Hunt, and Vijay Lathi. All three were previously associated with Sprout Group. The document lists their educational backgrounds and extensive board memberships across various pharmaceutical and medical technology companies.
This document is an Executive Summary for 'New Leaf Ventures III, L.P.' (NLV-III), a healthcare technology investment fund targeting $375 million in capital commitments. It details the history of the management company, New Leaf Venture Partners, outlining previous funds (NLV-I and NLV-II) and their affiliation with Sprout Group/Credit Suisse. The document lists the Managing Directors and outlines the fund's strategy to invest in 24-28 U.S.-based healthcare companies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional document production.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity